Elicit: Unmet Needs in Uncontrolled Gout Treatment (public)

Unmet Needs in Uncontrolled Gout Treatment

What are needs unmet by the current treatment patterns for patients uncontrolled gout?

Unmet needs in uncontrolled gout include ongoing flares and tophi formation despite standard therapy, restricted treatment options for patients with kidney or heart disease, drug safety concerns, and barriers to optimal care management.

Abstract

Patients with uncontrolled gout face several challenges that current treatment patterns do not address. Studies report that patients with refractory or treatment‐failure gout continue to experience frequent flares, tophaceous deposits, and high healthcare use despite conventional urate‐lowering therapy. One set of papers finds that 15–32% of patients remain difficult to treat even with aggressive management.

Unmet needs include:

Persistent disease activity—with recurrent flares and tophi formation—despite standard therapy.
Limited safe and effective options for patients with comorbid conditions (notably chronic kidney and cardiovascular disease), given dosing constraints and increased adverse effects.
Safety and tolerability issues, such as immunogenicity and infusion reactions with agents like pegloticase.
Barriers to optimal management arising from poor treatment adherence, inadequate patient–provider communication, and clinical inertia.

These studies indicate that existing treatment strategies often fall short for patients with uncontrolled gout, leaving a need for approaches that directly address these clinical and management gaps.

Methods

We analyzed 40 sources from an initial pool of 997, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question. More on methods

Papers identified with Elicit search

n = 997

Papers screened using:

Target Population, Unmet Needs Focus, Treatment and Outcomes, Adult Population, Study Design and Data Quality, Patient Population Appropriateness, Clinical Relevance, Study Size and Publication Type
n = 997

Papers screened out

n = 957

Papers included for extraction

n = 40

Paper search

Using your research question "What are needs unmet by the current treatment patterns for patients uncontrolled gout?", we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 997 papers most relevant to the query.

Screening

We screened in sources based on their abstracts that met these criteria:

Target Population: Does the study include patients with gout that is explicitly described as uncontrolled, refractory, difficult-to-treat, or inadequately controlled?
Unmet Needs Focus: Does the study identify, describe, or measure unmet clinical needs, treatment gaps, patient dissatisfaction, or suboptimal outcomes in gout management?
Treatment and Outcomes: Does the study report on current treatment patterns, therapeutic approaches, management strategies, or patient outcomes related to treatment effectiveness for gout?
Adult Population: Does the study focus on adult patients (≥18 years of age)?
Study Design and Data Quality: Is the study design a randomized controlled trial, observational study, qualitative study, systematic review, or meta-analysis that reports original data or synthesized evidence?
Patient Population Appropriateness: Does the study avoid focusing exclusively on well-controlled or successfully managed gout patients?
Clinical Relevance: Does the study avoid being limited to basic science, in vitro, animal research, or focusing solely on acute gout attacks without chronic management considerations?
Study Size and Publication Type: Does the study avoid being a case report or case series with fewer than 10 patients, conference abstract, editorial, or commentary without original data?

We considered all screening questions together and made a holistic judgment about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Study Design

Specify the type of study design (e.g., randomized controlled trial, systematic review, observational study, case-control study).

Look in the methods section for explicit description of study design. If not clearly stated, infer from study characteristics:

Presence of control/comparison group
Randomization
Prospective vs. retrospective data collection

If multiple design elements are present, list all applicable types. If uncertain, note “unclear” and provide reasoning.

Patient Population Characteristics

Extract detailed characteristics of study participants related to gout and treatment:

Specific gout condition (e.g., uncontrolled gout, chronic gout)
Comorbidities (especially chronic kidney disease)
Mean/median age
Percentage with treatment-refractory symptoms
Prior treatment history

Look in methods (participant selection) and results (baseline characteristics) sections. If ranges or multiple subgroups exist, report full range or all subgroups.

Specific Treatment Interventions

List all treatment interventions used in the study:

Medication names
Dosages
Frequency of administration
Duration of treatment

Distinguish between:

Acute gout treatments
Urate-lowering therapies
Prophylactic treatments

Capture any novel or emerging treatments mentioned. If multiple intervention arms exist, detail each separately.

Source: Primarily methods and intervention sections of the paper.

Treatment Outcomes

Identify and extract:

Primary outcome measures
Specific metrics used to assess treatment effectiveness
Measures of unmet treatment needs (e.g., persistent symptoms, treatment failure rates)

Include:

Numerical results
Statistical significance
Confidence intervals (if available)

Prioritize patient-centered outcomes related to gout management and symptom control.

Source: Results section, with potential supplementary information in discussion.

Limitations and Unmet Needs

Extract explicit statements about:

Limitations in current gout treatment approaches
Specific challenges in managing uncontrolled gout
Recommendations for future research or treatment strategies

Look in:

Discussion section
Conclusion paragraphs
Limitations subsection

Capture direct quotes or paraphrased insights about treatment gaps or unresolved clinical challenges.

Results

Characteristics of Included Studies

Study	Study Focus	Patient Population	Treatment Context	Key Findings Related to Unmet Needs
Morlock et al., 2024	Claims analysis of uncontrolled gout prior to pegloticase	Chronic uncontrolled gout, high comorbidity burden (chronic kidney disease, cardiovascular disease)	Pre-pegloticase, mostly prior oral urate-lowering therapies	Progressive increase in flares, tophi, and healthcare resource utilization; earlier identification and therapy needed
Keenan, 2017	Review of limitations in gout care standards	Chronic gout	Primary care, guideline adherence	Poor adherence to guidelines, patient/provider barriers, need for new therapies
Pascart and Lioté, 2018	State-of-the-art review of gout	Uncomplicated and complicated gout, comorbidities	General management, imaging, adherence	Low adherence, clinical inertia, comorbidity challenges
Richette et al., “Updated EULAR Recommendations”	Updated EULAR guidelines	All gout, including severe/refractory	Gout often poorly managed; need for alternative options in severe cases
Richette et al., 2014	Systematic review and Delphi for EULAR update	Uncontrolled, chronic, refractory gout; comorbidities	Allopurinol, febuxostat, uricosurics, pegloticase	Suboptimal management, limited urate-lowering therapy availability, need for more trials
Rai et al., 2018	Systematic review of barriers to gout care	Episodic gout, patient/provider perspectives	Global, qualitative	Knowledge gaps, system barriers, practical challenges
Terkeltaub, 2010	Review of new strategies in gout	Complex gout, comorbidities	Dietary, pharmacologic, emerging therapies	Complexity due to comorbidities, need for novel approaches
Fels and Sundy, 2008	Review of refractory gout	Refractory gout, chronic kidney disease	Allopurinol, febuxostat, uricase	Dose limitations, need for new therapies (interleukin-1 inhibition)
Spencer et al., 2012	Qualitative study of barriers	Gout patients, providers	General practice	Misconceptions, lack of knowledge, suboptimal care
Soskind et al., 2017	Review of updated treatments	Gout, difficult-to-treat	Acute and chronic, novel agents	Need for targeted therapies for refractory cases

Across 40 studies, the following patterns were identified in patient populations, treatment contexts, and unmet needs in gout care:

Patient Populations Studied:

21 studies included uncontrolled, refractory, or treatment-failure gout.
22 studies included gout with comorbidities (such as chronic kidney disease, cardiovascular disease).
9 studies included chronic or complicated gout (not specifically uncontrolled).
3 studies focused on gout in chronic kidney disease or end-stage renal disease.
2 studies included general or unspecified gout.
2 studies were qualitative (patients/providers).
In 5 studies, we did not find mention of the patient population.

Treatment Contexts:

31 studies discussed urate-lowering therapy, including allopurinol, febuxostat, uricosurics, and pegloticase.
7 studies discussed non-urate-lowering pharmacologic treatments (nonsteroidal anti-inflammatory drugs, colchicine, corticosteroids, interleukin-1 blockers, etc.).
2 studies described nurse, pharmacist, or multidisciplinary interventions.
4 studies focused on primary, rheumatology, or general practice care.
5 studies addressed guideline adherence or management models.
In 2 studies, we did not find mention of the treatment context.

Key Findings Related to Unmet Needs:

18 studies identified poor adherence or suboptimal management as an unmet need.
13 studies highlighted the need for new or alternative therapies, especially for refractory or comorbid cases.
11 studies reported comorbidity-related challenges or limitations in treatment.
5 studies described knowledge gaps, misconceptions, or education needs among patients or providers.
4 studies identified system or provider barriers or clinical inertia.
4 studies reported poor quality of life or high disease burden.
3 studies noted limited treatment options in chronic kidney disease or end-stage renal disease.
5 studies called for improved guidelines or protocols.
1 study each identified high healthcare resource utilization or costs and the need for earlier therapy.

We did not find studies that addressed unmet needs outside these categories.

Thematic Analysis

Refractory and Difficult-to-Treat Gout

A subset of patients with refractory or treatment-failure gout experience persistent symptoms, frequent flares, and tophaceous deposits despite aggressive therapy.
These patients often have multiple comorbidities, particularly chronic kidney disease, which further complicates management.
Across studies, 15–32% of patients on urate-lowering therapy remain difficult to treat, with high rates of nonresponse to advanced therapies such as pegloticase. Immunogenicity and infusion reactions are common limitations.
The included studies emphasize the need for alternative strategies, including immunomodulation and last-resort biologics, but also note that these approaches have their own limitations and risks.

Treatment Limitations in Patients with Comorbidities

Comorbidities, especially chronic kidney disease and cardiovascular disease, are major barriers to effective gout management.
Standard therapies such as nonsteroidal anti-inflammatory drugs and colchicine are often contraindicated or require dose adjustments, leading to suboptimal control.
Allopurinol dosing is frequently limited by renal function, and newer agents like febuxostat and pegloticase have limited safety data in advanced chronic kidney disease.
The included studies report a critical unmet need for safe and effective therapies tailored to patients with significant comorbidities, as well as more research to inform evidence-based guidelines for these populations.

Safety and Tolerability Concerns with Current Therapies

Safety and tolerability issues are prominent, particularly in patients with comorbidities.
Adverse effects, drug interactions, and immunogenicity (notably with pegloticase) limit the use of both traditional and novel therapies.
Infusion reactions, antibody development, and high rates of flares during initiation of biologic therapies are significant concerns.
There is also a high prevalence of opioid use in uncontrolled gout populations, reflecting inadequate pain control and the limitations of current anti-inflammatory options.

Adherence Challenges and Clinical Management Gaps

Adherence to urate-lowering therapy and guideline-recommended care is consistently suboptimal, with both patient and provider factors contributing.
Barriers include lack of education, misconceptions about gout, system-level constraints (such as time and incentives), and poor follow-up.
Even in settings with high urate-lowering therapy use, a substantial proportion of patients do not achieve target serum urate levels or remain symptomatic.
The two studies on nurse-led and multidisciplinary interventions report improved adherence and outcomes, but these approaches are not standard practice.
Several studies report that lack of patient-provider communication, irregular monitoring, and absence of individualized care plans contribute to suboptimal management.

References

R. Keenan(2017). Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. Clinical Therapeutics.
T. Pascart, F. Lioté(2018). Gout: state of the art after a decade of developments. Rheumatology.
P. Richette, M. Doherty, E. Pascual, V. Barskova, F. Becce, and 17 more (2014). SAT0531 Updated EULAR Evidence-Based Recommendations for the Management of Gout.
P. Richette, M. Doherty, E. Pascual, V. Barskova, F. Becce, and 19 more (2014). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases.
S. Rai, Hyon K. Choi, Sally H J Choi, A. Townsend, K. Shojania, and 1 more (2018). Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology.
R. Terkeltaub (2010). Update on gout: new therapeutic strategies and options. Nature Reviews Rheumatology.
E. Fels, J. Sundy(2008). Refractory gout: what is it and what to do about it?. Current Opinion in Rheumatology.
Karen Spencer, A. Carr, M. Doherty (2012). Patient and provider barriers to effective management of gout in general practice: a qualitative study. Annals of the Rheumatic Diseases.
R. Soskind, Daniel T. Abazia, M. Bridgeman (2017). Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opinion on Pharmacotherapy.
R. Curiel, N. J. Guzman (2012). Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Seminars in Arthritis & Rheumatism.